Tarsus paid $270,000,000 in cash and issued 2,908,692 shares at closing. Up to $350,000,000 in milestones and tiered revenue sharing on gildeuretinol sales remain to be paid.
The merger agreement signed July 31, 2026 also provides milestone payments of up to $350,000,000. Closing needs Hart-Scott-Rodino clearance, and Tarsus expects to complete the deal in 2026.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $204.6 million, plus short-term investments of $245.1 million, $449.7 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Tarsus Pharmaceuticals
Is Tarsus Pharmaceuticals involved in a merger or acquisition?
Our latest story on this, dated Aug 6, 2026: "Tarsus agrees to buy Alkeus for $270,000,000 in cash and $180,000,000 in stock". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals, Inc. trades under the ticker TARS on NASDAQ.
Where is Tarsus Pharmaceuticals listed?
Tarsus Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of Tarsus Pharmaceuticals?
The SEC Central Index Key (CIK) for Tarsus Pharmaceuticals, Inc. is 1819790. Its filings are on SEC EDGAR.
How many shares does Tarsus Pharmaceuticals have outstanding?
43,882,996 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Tarsus Pharmaceuticals listed under?
Our directory records Tarsus Pharmaceuticals, Inc. under United States.
What does Tarsus Pharmaceuticals do?
Our directory classifies Tarsus Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Tarsus Pharmaceuticals?
The ISIN recorded for Tarsus Pharmaceuticals, Inc. is US87650L1035.
Does aibio.space cover Tarsus Pharmaceuticals?
aibio.space lists Tarsus Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Tarsus Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What was Tarsus Pharmaceuticals's revenue last year?
$451.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Tarsus Pharmaceuticals profitable?
Tarsus Pharmaceuticals, Inc. reported a net loss of $66.4 million for the fiscal year ended Dec 31, 2025, and used $12.5 million of cash in operations, per its annual report to the SEC.
How much does Tarsus Pharmaceuticals spend on research and development?
$64.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Tarsus Pharmaceuticals have?
$449.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Tarsus Pharmaceuticals (TARS) stock news?
Our latest story on Tarsus Pharmaceuticals, dated Sep 10, 2026: "Tarsus Pharmaceuticals completes Alkeus acquisition with $270,000,000 in cash up front". Tarsus paid $270,000,000 in cash and issued 2,908,692 shares at closing. Up to $350,000,000 in milestones and tiered revenue sharing on gildeuretinol sales remain to be paid. Source.
Investor discussion: Tarsus Pharmaceuticals
Members talk about Tarsus Pharmaceuticals (TARS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Tarsus Pharmaceuticals, newest first. Each line links the filing it comes from.
Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,8.01,9.01). Source
Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:TARS on TradingView.
SEC filings and registration
SEC name
Tarsus Pharmaceuticals, Inc.
CIK
1819790
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
TARS (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618
Phone
(949) 409-9820
Shares outstanding
43,882,996 as of 2026-07-30 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Tarsus Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TARS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio